Variations of the proprotein convertase subtilisin/kexin type 9 gene in coronary artery disease

被引:6
|
作者
Chiang, Shih-Min [1 ]
Yang, Yi-Sun [1 ,2 ,3 ]
Yang, Shun-Fa [1 ,4 ]
Tsai, Chin-Feng [5 ]
Ueng, Kwo-Chnag [3 ,5 ]
机构
[1] Chung Shan Med Univ, Inst Med, Taichung, Taiwan
[2] Chung Shan Med Univ Hosp, Div Endocrinol & Metab, Dept Internal Med, Taichung, Taiwan
[3] Chung Shan Med Univ, Sch Med, Taichung, Taiwan
[4] Chung Shan Med Univ Hosp, Dept Med Res, Taichung, Taiwan
[5] Chung Shan Med Univ Hosp, Div Cardiol, Dept Internal Med, 110,Sec1,Jianguo N Rd, Taichung 40201, Taiwan
关键词
Proprotein Convertase Subtilisin/Kexin Type 9; coronary artery disease; diabetes; polymorphisms; Taiwanese; genotyping; LIPOPROTEIN CHOLESTEROL LEVELS; PCSK9; GENE; SEQUENCE VARIATIONS; E670G POLYMORPHISM; RISK; MUTATIONS; SEVERITY; LDL;
D O I
10.1177/0300060519839519
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objective: Coronary artery disease (CAD) is the principal cause of mortality and morbidity worldwide. Studies have provided controversial results regarding whether variations in the proprotein convertase subtilisin/kexin type 9 gene (PCSK9) are risk factors for CAD. In this study, we evaluated the risk factors associated with PSCK9 genotypes and CAD in the Taiwanese population. Methods: A total of 501 patients diagnosed with CAD by angiography and 334 CAD-free controls were recruited. Two single nucleotide polymorphisms of PSCK9 (rs505151 and rs529787) were genotyped. Results: The prevalence of a positive family history for CAD was significantly higher in individuals carrying the AG+GG genotype of the PSCK9 rs505151 polymorphism. Among CAD patients with a positive family history, the prevalence of diabetes mellitus was significantly higher in those carrying the AG+GG genotype of the PSCK9 rs505151 polymorphism (73.3%) than in those carrying the AA genotype (39.2%). Conclusion: In CAD patients, the AG genotype of PSCK9 rs505151 is associated with diabetes and a positive family history of CAD.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Proprotein convertase subtilisin-kexin type 9 as a biomarker for the severity of coronary artery disease
    Li, Sha
    Zhang, Yan
    Xu, Rui-Xia
    Guo, Yuan-Lin
    Zhu, Cheng-Gang
    Wu, Na-Qiong
    Qing, Ping
    Liu, Geng
    Dong, Qian
    Li, Jian-Jun
    [J]. ANNALS OF MEDICINE, 2015, 47 (05) : 386 - 393
  • [2] Proprotein Convertase Subtilisin/Kexin Type 9
    Lu
    Daugherty
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2016, 36 (04) : E32 - E32
  • [3] Proprotein convertase subtilisin/kexin type 9 in kidney disease
    Schmit, David
    Fliser, Danilo
    Speer, Thimoteus
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34 (08) : 1266 - 1271
  • [4] Proprotein convertase subtilisin/kexin type 9 inhibition
    Marais, David A.
    Blom, Dirk J.
    Petrides, Francine
    Goueffic, Yann
    Lambert, Gilles
    [J]. CURRENT OPINION IN LIPIDOLOGY, 2012, 23 (06) : 511 - 517
  • [5] Thyroid function and proprotein convertase subtilisin/kexin type 9 levels in euthyroid subjects with coronary artery disease
    Li, S.
    Xu, R. -X.
    Guo, Y. -L.
    Zhang, Y.
    Zhu, C. -G.
    Sun, J.
    Li, J. J.
    [J]. EUROPEAN HEART JOURNAL, 2015, 36 : 931 - 931
  • [6] Proprotein convertase subtilisin-kexin type 9 as a biomarker for the development and severity of coronary artery disease in general population
    Li, S.
    Xu, R. -X.
    Zhang, Y.
    Guo, Y. -L.
    Zhu, C. -G.
    Wu, N. -X.
    Qing, P.
    Liu, G.
    Dong, Q.
    Li, J. J.
    [J]. EUROPEAN HEART JOURNAL, 2015, 36 : 930 - 930
  • [7] Role of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with coronary artery disease undergoing percutaneous coronary intervention
    Navarese, Eliano P.
    Kolodziejczak, Michalina
    Petrescu, Aniela
    Wernly, Bernhard
    Lichtenauer, Michael
    Lauten, Alexander
    Buffon, Antonino
    Wanha, Wojciech
    Pestrichella, Vincenzo
    Sardella, Gennaro
    Contegiacomo, Gaetano
    Tantry, Udaya
    Bliden, Kevin
    Kubica, Jacek
    Gurbel, Paul A.
    [J]. EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2018, 16 (06) : 419 - 429
  • [8] Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors
    Julius U.
    Tselmin S.
    Schatz U.
    Fischer S.
    Bornstein S.R.
    [J]. Clinical Research in Cardiology Supplements, 2019, 14 (Suppl 1) : 45 - 50
  • [9] Proprotein convertase subtilisin/kexin type 9 and lipid metabolism
    Spolitu, Stefano
    Dai, Wen
    Zadroga, John A.
    Ozcan, Lale
    [J]. CURRENT OPINION IN LIPIDOLOGY, 2019, 30 (03) : 186 - 191
  • [10] Depressive Symptoms and Proprotein Convertase Subtilisin/Kexin Type 9
    Macchi, C.
    Buoli, M.
    Favero, C.
    Pesatori, A.
    Vigna, L.
    Corsini, A.
    Sirtori, C.
    Bollati, V.
    Ruscica, M.
    [J]. JOURNAL OF MOLECULAR DIAGNOSTICS, 2020, 22 (05): : S92 - S92